Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 16, 2023

VV116 vs Nirmatrelvir–Ritonavir for Oral Treatment of COVID-19

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19
N. Engl. J. Med 2022 Dec 28;[EPub Ahead of Print], Z Cao, W Gao, H Bao, H Feng, S Mei, P Chen, Y Gao, Z Cui, Q Zhang, X Meng, H Gui, W Wang, Y Jiang, Z Song, Y Shi, J Sun, Y Zhang, Q Xie, Y Xu, G Ning, Y Gao, R Zhao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading